Discover 657 paid clinical trials in Charleston, South Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
for
Prostate Cancer (Adenocarcinoma)
Location: Charleston SC, Monroe NC, Rock Hill SC, Matthews NC,
Sponsor: Canadian Cancer Trials Group
Sex: Male
Age: 18+
Code: NCT06592924
Phase 3, Recruiting
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Location: Charleston SC, North Charleston SC, Myrtle Beach SC,
Sponsor: UroGen Pharma Ltd.
Sex: All
Age: 18+
Code: NCT06774131
Phase 3, Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
for
Lymphoma, Large B-Cell, Diffuse
Location: Charleston SC, Charlotte NC, Jacksonville FL,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06890884
Phase 2, Recruiting
Telerehabilitation In The Home After Stroke
for
Stroke
Location: Charleston SC, Jacksonville FL, Chapel Hill NC,
Sponsor: University of California, Los Angeles
Sex: All
Age: 18 - 70+
Code: NCT06682429
Recruiting
Combining rTMS & Aerobic Exercise to Treat Depression and Improve Post-Stroke Walking
for
Stroke, Depression - Major Depressive Disorder,
Location: Charleston SC, Durham NC
Sponsor: Medical University of South Carolina
Sex: All
Age: 21+
Code: NCT07050355
Recruiting
Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha PCD-CT Before TAVI Procedure
for
Coronary Artery Disease, Aortic Valve Stenosis,
Location: Charleston SC
Sponsor: Semmelweis University
Sex: All
Age: 18+
Code: NCT07016477
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer